Kadcyla cut risk of disease recurrence vs. Herceptin in HER2-positive early breast cancer with residual disease after neoadjuvant treatment

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Genentech said the phase III KATHERINE study met its primary endpoint, showing Kadcyla (ado-trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death (invasive disease-free survival) by 50 percent (HR=0.50, 95% CI 0.39-0.64, p<0.0001) compared to Herceptin (trastuzumab) as an adjuvant treatment in people with HER2-positive early breast cancer who have residual disease (pathological invasive residual disease in the breast and/or axillary nodes) present following neoadjuvant treatment.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

An updated version of President Trump’s budget request published on May 2 comes as a disappointment for those who hoped that the White House would rethink the draconian cuts contained in an earlier, confidential version of the document that ended up being leaked to the press. 
“We stand at the edge of discovery, and on the brink of losing it,” said Patricia M. LoRusso, the 2024-2025 president of the American Association for Cancer Research. “I believe this is the most scientifically promising moment in the history of cancer research.” 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login